Gastric and gastro-oesophageal cancer therapy.
Gastric and gastro-oesophageal cancers represent a global health problem. In recent years, there has been a marked increase in the incidence of proximal gastric and distal oesophageal adenocarcinomas. Surgery is the primary therapy for localised gastric or gastro-oesophageal cancer; however, patients treated with surgery have high rates of local and distant relapse as well as an unacceptably low 5-year survival rate. Chemoradiation and preoperative chemotherapy can play an important role for these patients. The outcome of patients with metastatic disease is very poor but a number of newer chemotherapy agents, such as docetaxel, oxaliplatin and S-1, have been identified and some have shown promising results. This article reviews recent trials on localised and metastatic gastric and gastro-oesophageal cancers.
Das
Prajnan
P
Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. PrajDas@mdanderson.org
Ajani
Jaffer A
JA
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000532:radiotherapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000532:radiotherapy
D000970:Antineoplastic Agents